{"id":261,"date":"2024-01-03T10:00:00","date_gmt":"2024-01-03T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=261"},"modified":"2025-09-08T13:15:36","modified_gmt":"2025-09-08T13:15:36","slug":"china-bd-2024-allorion-and-astrazeneca-enters-an-option-and-global-license-on-egfr-l858r-allosteric-inhibitor-asset","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2024\/261.html","title":{"rendered":"[China BD 2024] Allorion and AstraZeneca enters an Option and Global License on EGFR L858R Allosteric Inhibitor Asset"},"content":{"rendered":"\n<p>Announced Date: 2024-01-02 (January\u00a02, 2024)<\/p>\n\n\n\n<p>Asset Name:  Undisclosed<\/p>\n\n\n\n<p>Licensor (Seller): Allorion Therapeutics (China)<\/p>\n\n\n\n<p>Licensee (Buyer): AstraZeneca<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: Small Molecule<\/p>\n\n\n\n<p>Asset Target: EGFR L858R Allosteric Inhibitor<\/p>\n\n\n\n<p>Potential Indication: treatment for advanced EGFR-mutant non-small cell lung cancer (NSCLC)<\/p>\n\n\n\n<p>Current Stage: Preclinical<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>AstraZeneca will be granted an exclusive option to license a novel EGFR L858R allosteric inhibitor to develop and commercialize globally.\u00a0<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Payment Detail:<\/p>\n\n\n\n<p>Allorion is eligible to receive:<\/p>\n\n\n\n<p>Upfront and near-term payments of up to\u00a0$40 million, <\/p>\n\n\n\n<p>Development and commercial milestone payments of over\u00a0$500 million.<\/p>\n\n\n\n<p> Tiered royalties on net sales worldwide.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/www.prnewswire.com\/news-releases\/allorion-therapeutics-announces-exclusive-option-and-global-license-agreement-for-novel-preclinical-stage-egfr-l858r-allosteric-inhibitor-program-with-astrazeneca-302023562.html\">Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca (prnewswire.com)<\/a><\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Note:<\/p>\n\n\n\n<p>Chinese Name of Allorion Therapeutics, \u5b89\u9510\u751f\u7269<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2024-01-02 (January\u00a02, 2024) Asset Name: Undisclosed Licensor (Seller): Allorion Therapeutics (China) Licensee (Buyer): AstraZeneca &hellip; <a title=\"[China BD 2024] Allorion and AstraZeneca enters an Option and Global License on EGFR L858R Allosteric Inhibitor Asset\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2024\/261.html\"><span class=\"screen-reader-text\">[China BD 2024] Allorion and AstraZeneca enters an Option and Global License on EGFR L858R Allosteric Inhibitor Asset<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-261","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/261","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=261"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/261\/revisions"}],"predecessor-version":[{"id":262,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/261\/revisions\/262"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=261"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=261"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=261"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}